Last reviewed · How we verify
SODIUM SUCCINATE
Sodium succinate is a marketed drug primarily indicated for allergic states, with a key composition patent expiring in 2028. Its mechanism of providing succinate ions to regulate cellular processes offers a unique therapeutic approach in managing allergic conditions. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | SODIUM SUCCINATE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1971 |
Approved indications
- Allergic States
- Dermatologic Diseases
- Endocrine Disorders
- Gastrointestinal Diseases
- Hematologic Disorders
- Miscellaneous
- Neoplastic Diseases
- Nervous System
- Ophthalmic Diseases
- Renal Diseases
- Respiratory Diseases
- Rheumatic Disorders
Common side effects
- Fluid retention
- Increased appetite
- Nausea
- Weight gain
- Hypertension
- Acne
- Insomnia
- Mood swings
- Headache
- Increased sweating
- Rash
- Edema
Serious adverse events
- Anaphylaxis
- Cardiac arrest
- Circulatory collapse
- Myocardial rupture
- Pulmonary edema
- Peptic ulcer with perforation and hemorrhage
- Aseptic necrosis of femoral and humeral heads
- Convulsions
- Increased intracranial pressure with papilledema
- Blindness associated with periocular injections
Drug interactions
- Aminoglutethimide
- Amphotericin B injection and potassium-depleting agents
- Macrolide antibiotics
- Anticholinesterases
- Oral anticoagulants (e.g., warfarin)
- Antidiabetics
- Antitubercular drugs (e.g., isoniazid)
- Cholestyramine
- Cyclosporine
- Digitalis glycosides
- Estrogens, including oral contraceptives
- Hepatic Enzyme Inducers (e.g., barbiturates, phenytoin, carbamazepine, rifampin)
Key clinical trials
- Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma (PHASE2)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis (PHASE2)
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy (PHASE1)
- 1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study (NA)
- Comparison of Submucosal Dexamethasone and Methylprednisolone in Postoperative Sequelae of Parasymphsis Fractures (PHASE2)
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- IA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SODIUM SUCCINATE CI brief — competitive landscape report
- SODIUM SUCCINATE updates RSS · CI watch RSS